Dawn Broderick
Internal Medicine · Olney, MDNPI 1801899489
Payments from drug & device makers
Across 214 payments — averaging $18.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$913
- Pfizer$476
- Novo Nordisk$390
- Lilly USA, LLC$352
- AstraZeneca$298
- Merck$262
- plus $1K from 20 others
What the payments were for
- Food & beverage$3,848100%
- Education$60%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 55 | $913 |
| Pfizer | 21 | $476 |
| Novo Nordisk | 23 | $390 |
| Lilly USA, LLC | 17 | $352 |
| AstraZeneca | 18 | $298 |
| Merck | 17 | $262 |
| Amgen(2 entities) | 14 | $242 |
| Exact Sciences | 11 | $229 |
| Astellas Pharma US Inc | 5 | $89 |
| Therapeuticsmd, Inc. | 3 | $63 |
| Ironwood Pharmaceuticals, Inc | 4 | $60 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $45 |
| Idorsia Pharmaceuticals US Inc | 2 | $44 |
| Eisai Inc. | 3 | $42 |
| Sunovion Pharmaceuticals Inc. | 2 | $40 |
| Sanofi-aventis U.S. LLC | 2 | $37 |
| Johnson & Johnson | 1 | $36 |
| Biohaven Pharmaceuticals, Inc. | 2 | $34 |
| Boehringer Ingelheim | 2 | $33 |
| Kowa Pharmaceuticals America, Inc. | 2 | $29 |
| Radius Health, Inc. | 1 | $29 |
| Amarin Pharma, Inc. | 2 | $27 |
| Amneal Pharmaceuticals LLC | 1 | $26 |
| Genentech USA, Inc. | 1 | $21 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $20 |
| GSK | 1 | $19 |
How this compares
$3,854 in reported general payments places this provider in the 85th percentile of 2,979 internal medicine providers in Maryland.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 92 | $95,223 |
| OzempicSemaglutide | 40 | $52,711 |
| RybelsusSemaglutide | 30 | $47,950 |
| MounjaroTirzepatide | 47 | $46,814 |
| JardianceEmpagliflozin | 22 | $36,584 |
| JanuviaSitagliptin Phosphate | 17 | $27,357 |
| Repatha SureclickEvolocumab | 11 | $17,478 |
| FarxigaDapagliflozin Propanediol | 14 | $16,190 |
| MyrbetriqMirabegron | 18 | $15,882 |
| Praluent PenAlirocumab | 12 | $12,807 |
| Breo ElliptaFluticasone/Vilanterol | 20 | $11,227 |
| LinzessLinaclotide | 11 | $9,762 |
| SynthroidLevothyroxine Sodium | 81 | $9,430 |
| TrintellixVortioxetine Hydrobromide | 12 | $6,072 |
| Spiriva HandihalerTiotropium Bromide | 11 | $5,933 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $390 | $100,66170 claims |
| PfizerEliquis, Paxlovid | $476 | $99,477121 claims |
| Lilly USA, LLCMounjaro | $352 | $46,81447 claims |
| Boehringer IngelheimJardiance | $33 | $36,58422 claims |
| MerckJanuvia | $262 | $27,35717 claims |
| AbbVieLinzess, Synthroid | $913 | $19,19292 claims |
| AstraZenecaFarxiga | $298 | $16,19014 claims |
| Astellas Pharma US IncMyrbetriq | $89 | $15,88218 claims |
| GSKBreo Ellipta | $19 | $11,22720 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $20 | $6,07212 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $26 | $2,222120 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,979 internal medicine providers in Maryland.
Other internal medicine in Olney
- Shishir KhetanRockville$52.1M
- Steven GellerElkridge$15.1M
- Mary HowellHagerstown$6.2M
- Kristen MarroneBaltimore$5.6M
- Jonathan CohenRockville$5M
- Andrea ApoloBethesda$4.8M
- Peta-Gay Jackson BoothBaltimore$3.6M
- Rahul PatelRockville$2.8M
- Mark YarchoanBaltimore$2.4M
- Marianne MannHighland$2.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.